Breast cancer is the most common malignancy in women worldwide. Metastasis is the
leading cause of high mortality in most cancers. Although predicting the early stage of breast …

Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …

Background Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-
directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable …

Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have
shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this …

Transitions between epithelial and mesenchymal phenotypes–the epithelial to
mesenchymal transition (EMT) and its reverse the mesenchymal to epithelial transition …

Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a
potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug …

Triple-negative breast cancer (TNBC) is characterised by poor outcomes and a historical
lack of targeted therapies. Dysregulation of signalling through the phosphoinositide 3 (PI3) …

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer,
which is characterized by the lack of clinically significant expression of estrogen receptor …

Background Treatment options for women presenting with triple negative breast cancer
(TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with …

Matrix metalloproteinases (MMPs) have been implicated in diverse roles in breast cancer
development and progression. While many of the different MMPs expressed in breast cancer …